Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | ANPEP | P15144 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5217857 | 0.87 | ALDH1A1 (0.47) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL5144567 | 0.84 | SLC18A3 (0.43) | ALDH1A1USP2MEN1KMT2ASLC18A3 | |
| SCHEMBL12014432 | 0.84 | ALDH1A1 (0.45) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL5144884 | 0.83 | ABCB1 (0.44) | ALDH1A1USP2MEN1KMT2AL3MBTL1 | |
| SCHEMBL6834391 | 0.81 | ALDH1A1 (0.43) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL18751376 | 0.81 | ALDH1A1 (0.43) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL2064956 | 0.81 | ALDH1A1 (0.51) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL6836054 | 0.79 | NPC1 (0.58) | ALDH1A1NPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL22480297 | 0.77 | ALDH1A1 (0.53) | ALDH1A1USP2NPC1MEN1KMT2A | |
| SCHEMBL5147209 | 0.76 | SLC18A3 (0.39) | ALDH1A1MEN1KMT2ASLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1575591-A4 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMA INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-7238679-B2 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1453492-B1 | USE OF QUINAZOLINES TO TREAT T-CELL MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | disclosed |
| US-7157467-B2 | Administering compound such as 6-methoxy-4-(2,3-methylenedioxyanilino)-7-(3-morpholinopropoxy)quinazoline for therapy of an autoimmune disease or medical condition selected from transplant rejection and rheumatoid arthritis | ASTRAZENECA AB (SE) | 2007-01-02 | — | — | US | disclosed |
| US-7115615-B2 | Quinazoline derivatives | ASTRAZENECA (SE) | 2006-10-03 | — | — | US | disclosed |
| EP-1575591-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2005-09-21 | — | — | EP | disclosed |
| US-6939866-B2 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2005-09-06 | — | — | US | disclosed |
| US-6849625-B2 | Quinazoline derivatives with anti-tumour activity | ASTRAZENECA AB (SE) | 2005-02-01 | — | — | US | disclosed |
| US-20050014773-A1 | Therapeutic use | ASTRAZENACA AB (SE) | 2005-01-20 | — | — | US | disclosed |
| US-20040171586-A1 | Heterocycles and uses thereof | ARIAD PHARMACEUTICALS, INC. | 2004-09-02 | — | — | US | disclosed |
| WO-2004058267-A1 | HETEROCYCLES AND USES THEREOF | ARIAD PHARMACEUTICALS, INC. (US) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014773-A1 | Therapeutic use | CD4, HLA-DRB1, CD74 | ALDH1A1 315/4885USP2 4492/4885NPC1 3182/4885 |
| US-20040171586-A1 | Heterocycles and uses thereof | CBR1, CBR3, RCOR1 | ALDH1A1 3956/4885USP2 4093/4885NPC1 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.